美国 · SEC FORM 4
Cidara Therapeutics, Inc.
CDTX · — · CIK 0001610618 · Healthcare
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-06-26 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-06-26 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 2,272,727 | USD 44.00 | USD 99,999,988 | SEC 申报 ↗ |
| 2025-06-03 | Mineo Chrysa | 买入 (P) | Common Stock | 1,050 | USD 23.44 | USD 24,612 | SEC 申报 ↗ |
| 2025-06-02 | Mineo Chrysa | 买入 (P) | Common Stock | 2,270 | USD 21.71 | USD 49,282 | SEC 申报 ↗ |
| 2024-06-07 | Stein Jeffrey | 买入 (P) | Common Stock | 8,000 | USD 13.21 | USD 105,680 | SEC 申报 ↗ |
| 2023-08-14 | Tari Leslie | 买入 (P) | Common Stock | 10,000 | USD 0.97 | USD 9,700 | SEC 申报 ↗ |
| 2023-08-08 | Stein Jeffrey | 买入 (P) | Common Stock | 50,000 | USD 0.96 | USD 48,000 | SEC 申报 ↗ |
| 2023-03-27 | Stein Jeffrey | 买入 (P) | Common Stock | 50,000 | USD 1.04 | USD 52,000 | SEC 申报 ↗ |
| 2021-11-12 | Stein Jeffrey | 买入 (P) | Common Stock | 50,000 | USD 1.59 | USD 79,500 | SEC 申报 ↗ |
| 2021-11-12 | Shah Preetam | 买入 (P) | Common Stock | 20,000 | USD 1.54 | USD 30,800 | SEC 申报 ↗ |
| 2021-09-13 | Franson Timothy R | 买入 (P) | Common Stock | 7,000 | USD 2.12 | USD 14,840 | SEC 申报 ↗ |
| 2021-08-19 | Stein Jeffrey | 买入 (P) | Common Stock | 10,000 | USD 1.79 | USD 17,900 | SEC 申报 ↗ |
| 2021-08-18 | Stein Jeffrey | 买入 (P) | Common Stock | 40,000 | USD 1.72 | USD 68,800 | SEC 申报 ↗ |
| 2020-11-10 | Stein Jeffrey | 买入 (P) | Common Stock | 2,500 | USD 40.01 | USD 100,025 | SEC 申报 ↗ |
| 2020-11-10 | Stein Jeffrey | 买入 (P) | Common Stock | 50,000 | USD 2.00 | USD 100,000 | SEC 申报 ↗ |
| 2020-11-10 | Levine James E. | 买入 (P) | Common Stock | 50,000 | USD 2.01 | USD 100,500 | SEC 申报 ↗ |
Form 4 申报证据
25 transaction lines in the latest 365-day window; 129 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-01-07 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 期权行权/转换 (M) | Common Stock | 1,286,786 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-07 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | D (D) | Common Stock | 4,652,309 | USD 221.50 | USD 1,030,486,444 | SEC 申报 ↗ |
| 2026-01-07 | Ward Shane | D (D) | Common Stock | 25,083 | USD 221.50 | USD 5,555,884 | SEC 申报 ↗ |
展开近期 Form 4 证据 (20 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-01-07 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 期权行权/转换 (M) | Common Stock | 1,286,786 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-07 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | D (D) | Common Stock | 4,652,309 | USD 221.50 | USD 1,030,486,444 | SEC 申报 ↗ |
| 2026-01-07 | Ward Shane | D (D) | Common Stock | 25,083 | USD 221.50 | USD 5,555,884 | SEC 申报 ↗ |
| 2026-01-07 | Stein Jeffrey | D (D) | Common Stock | 75,640 | USD 221.50 | USD 16,754,260 | SEC 申报 ↗ |
| 2026-01-07 | Mineo Chrysa | D (D) | Common Stock | 3,320 | USD 221.50 | USD 735,380 | SEC 申报 ↗ |
| 2026-01-07 | KARBE FRANK | D (D) | Common Stock | 50,651 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-07 | Davarpanah Nicole Negar | D (D) | Common Stock | 20,886 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-07 | Bassler Bonnie L | D (D) | Common Stock | 15 | USD 221.50 | USD 3,322 | SEC 申报 ↗ |
| 2026-01-07 | BURGESS DANIEL D | D (D) | Common Stock | 150 | USD 221.50 | USD 33,225 | SEC 申报 ↗ |
| 2025-12-29 | Davarpanah Nicole Negar | 赠与 (G) | Common Stock | 450 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-22 | Stein Jeffrey | 赠与 (G) | Common Stock | 5,425 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-19 | Stein Jeffrey | 赠与 (G) | Common Stock | 10,638 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-17 | Stein Jeffrey | 赠与 (G) | Common Stock | 2,244 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-10 | Stein Jeffrey | 赠与 (G) | Common Stock | 33,072 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-10 | Ward Shane | 卖出 (S) | Common Stock | 9,959 | USD 220.08 | USD 2,191,777 | SEC 申报 ↗ |
| 2025-12-10 | Ward Shane | 期权行权/转换 (M) | Common Stock | 9,959 | USD 18.95 | USD 188,747 | SEC 申报 ↗ |
| 2025-12-10 | Ward Shane | 代扣税 (F) | Common Stock | 15,041 | USD 219.60 | USD 3,303,004 | SEC 申报 ↗ |
| 2025-12-10 | Stein Jeffrey | 代扣税 (F) | Common Stock | 2,285 | USD 219.60 | USD 501,786 | SEC 申报 ↗ |
| 2025-12-10 | KARBE FRANK | 代扣税 (F) | Common Stock | 7,290 | USD 219.60 | USD 1,600,884 | SEC 申报 ↗ |
| 2025-12-10 | Davarpanah Nicole Negar | 代扣税 (F) | Common Stock | 10,332 | USD 219.60 | USD 2,268,907 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CDTX |
| CIK | 0001610618 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | — |
数据覆盖
| 本地 Form 4 历史 | 129 transaction lines from 2020-01-02 to 2026-01-07 15 P purchase lines · 37 S sale lines · 77 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.